Literature DB >> 25633971

Bone and Joint Disorders in Acromegaly.

Kim M J A Claessen1, Gherardo Mazziotti, Nienke R Biermasz, Andrea Giustina.   

Abstract

Acromegaly is a chronic, progressive disease caused by a growth hormone (GH)-producing pituitary adenoma, resulting in elevated GH and insulin-like growth factor 1 concentrations. Following appropriate therapy (surgery, radiotherapy and/or medical treatment), many systemic GH-induced comorbid conditions improve considerably. Unfortunately, despite biochemical control, acromegaly patients suffer from a high prevalence of late manifestations of transient GH excess, significantly impairing their quality of life. In this overview article, we summarize the pathophysiology, diagnosis, clinical picture, disease course and management of skeletal complications of acromegaly, focusing on vertebral fractures and arthropathy.
© 2015 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25633971     DOI: 10.1159/000375450

Source DB:  PubMed          Journal:  Neuroendocrinology        ISSN: 0028-3835            Impact factor:   4.914


  15 in total

1.  Static and dynamic balances of patients with acromegaly and impact of exercise on balance.

Authors:  Ozlem Haliloglu; Nuri Topsakal; Filiz Camliguney; Ozge Polat Korkmaz; Serdar Sahin; Birol Cotuk; Pinar Kadioglu; Oya Erkut
Journal:  Pituitary       Date:  2019-10       Impact factor: 4.107

2.  Understanding and predicting fracture risk in acromegaly.

Authors:  Natasha M Appelman-Dijkstra; Nienke R Biermasz
Journal:  Endocrine       Date:  2017-02-02       Impact factor: 3.633

3.  Predictors of colonic pathologies in active acromegaly: single tertiary center experience.

Authors:  Raim Iliaz; Sema Ciftci Dogansen; Seher Tanrikulu; Gulsah Yenidunya Yalin; Bilger Cavus; Mine Gulluoglu; Filiz Akyuz; Sema Yarman
Journal:  Wien Klin Wochenschr       Date:  2018-07-30       Impact factor: 1.704

Review 4.  Acromegalic osteopathy.

Authors:  G Mazziotti; F Maffezzoni; S Frara; A Giustina
Journal:  Pituitary       Date:  2017-02       Impact factor: 4.107

5.  Arthropathy in acromegaly: a questionnaire-based estimation of motor disability and its relation with quality of life and work productivity.

Authors:  L M Fatti; B Cangiano; G Vitale; L Persani; G Mantovani; E Sala; M Arosio; P Maffei; F Dassie; M Mormando; A Giampietro; L Tanda; E R Masiello; E Nazzari; D Ferone; S Corbetta; E Passeri; F Guaraldi; S Grottoli; S Cannavò; M L T Torre; D Soranna; A Zambon; F Cavagnini; M Scacchi
Journal:  Pituitary       Date:  2019-10       Impact factor: 4.107

Review 6.  Current perspectives on the impact of clinical disease and biochemical control on comorbidities and quality of life in acromegaly.

Authors:  Federico Gatto; Claudia Campana; Francesco Cocchiara; Giuliana Corica; Manuela Albertelli; Mara Boschetti; Gianluigi Zona; Diego Criminelli; Massimo Giusti; Diego Ferone
Journal:  Rev Endocr Metab Disord       Date:  2019-09       Impact factor: 6.514

7.  Quality of Life in Patients with Acromegaly before and after Transsphenoidal Surgical Resection.

Authors:  Jing Gu; Shiyuan Xiang; Min He; Meng Wang; Yanfang Gu; Lingjuan Li; Zhiwen Yin
Journal:  Int J Endocrinol       Date:  2020-08-04       Impact factor: 3.257

Review 8.  Pegvisomant in acromegaly: an update.

Authors:  A Giustina; G Arnaldi; F Bogazzi; S Cannavò; A Colao; L De Marinis; E De Menis; E Degli Uberti; F Giorgino; S Grottoli; A G Lania; P Maffei; R Pivonello; E Ghigo
Journal:  J Endocrinol Invest       Date:  2017-02-07       Impact factor: 4.256

9.  Soluble Alpha Klotho in Acromegaly: Comparison With Traditional Markers of Disease Activity.

Authors:  Júnia R O L Schweizer; Katharina Schilbach; Michael Haenelt; Alexandre V Giannetti; Mariana F Bizzi; Beatriz S Soares; Eduardo Paulino; Jochen Schopohl; Sylvère Störmann; Antônio Ribeiro-Oliveira; Martin Bidlingmaier
Journal:  J Clin Endocrinol Metab       Date:  2021-07-13       Impact factor: 5.958

Review 10.  Human Growth and Growth Hormone: From Antiquity to the Recominant Age to the Future.

Authors:  Evan Graber; Edward O Reiter; Alan D Rogol
Journal:  Front Endocrinol (Lausanne)       Date:  2021-07-05       Impact factor: 5.555

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.